OBJECTIVE： To investigate the value of Huangkui capsules in preventing gadolinium contrast medium-induced nephrogenic systemic fibrosis. METHODS： 100 patients receiving MRA in our hospital from Jan. 2015 to Mar. 2016 were selected and divided into control group （52 cases） and observation group （48 cases） according to whether patients received Huangkui capsules or not after examination. Both groups received Gd-DTPA injection or Gadobenate dimeglumnine injection 0.2-0.6 mg/kg； control group didn’t accept any treatment after MRA； on the day of MRA， observation group was given Huangkui capsule， 2.5 g， tid， for 14 d. The renal function indexes， blood lipid levels， fibrosis indexes， the levels of CTGF and AngⅡ in serum and urine， inflammatory factor levels， the occurrence of nephrogenic systemic fibrosis and ADR were compared between 2 groups before examination and 14 d after examination. RESULTS： Before examination， there was no statistical significance in renal function indexes， blood lipid levels， fibrosis indexes， the levels of CTGF and AngⅡ， inflammatory factor levels between 2 groups （P＞0.05）. There was statistical significance in renal function indexes， blood lipid levels， fibrosis indexes， the levels of CTGF and AngⅡ， inflammatory factor levels of observation group between 14 d after examination and before examination， without statistical significance （P＞0.05）. The levels of BUN， Scr， LN， PC-Ⅲ and HA， serum and urine levels of CTGF and AngⅡ were significantly increased in control group， while Ccr level was decreased significantly； the changes of above indexes， TNF-α and IL-6 were more significant than observation group， with statistical significance （P＜0.05）. There was no statistical significance in blood lipid and hs-CRP before and after examination （P＞0.05）. The incidence of nephrogenic systemic fibrosis in observation group （1.92％） was significantly lower than in control group （18.75％）， with statistical significance （P＜0.05）. No ADR was found in 2 groups during treatment. CONCLUSIONS： Huangkui capsule can prevent gadolinium contrast medium-induced nephrogenic systemic fibrosis and renal function disorder after MRA to certain extent with good safety.